Non Regulatory Announcement Archives - Advanced Medical Solutions

Director Declaration

AdMedSol — Thu, 03 May 2018 12:27:15 +0000

RNS Number : 0457N

Advanced Medical Solutions Grp PLC

03 May 2018

3 May 2018

Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

Director Declaration

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that Chris Meredith, CEO, has been appointed a Non-Executive Director of Creavo Medical Technologies Ltd with effect from 1 May 2018.

Creavo Medical Technologies Ltd is a UK-based, privately-held medical device company that is developing innovative diagnostic techniques. The company was formed in 2014 to bring to market ground-breaking technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at Leeds University. It has facilities in Leeds and Coventry, UK.

– Ends –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director

Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Philippa Gardner

Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Daniel Adams / Patrick Robb / Gary Clarence

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAAJMBTMBTMBAP

The post Director Declaration appeared first on Advanced Medical Solutions.

Extended Product Claims for LiquiBand Exceed

AdMedSol — Tue, 03 Nov 2015 07:00:09 +0000

RNS Number : 3015E

Advanced Medical Solutions Grp PLC

03 November 2015

3 November 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

FDA Approves Extended Product Claims for LiquiBand^® Exceed™ Topical Skin Adhesive

Winsford, UK, 3 November 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.

These claims will allow AMS and partners to differentiate LiquiBand Exceed™ around wound coverage, yield and reuse, providing clinicians with the ability to increase the usage of a single applicator, saving time and cost.

The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both claims are unique FDA approved claims for the US Topical Skin Adhesive Market.

Following testing, LiquiBand^® Exceed™ was found to deliver best in class yield to support coverage up to 30cm of wound length¹, twice the amount advertised by market leading topical skin adhesive products². Due to the proprietary LiquiBand Exceed™ formula, the adhesive polymerises via skin contact using naturally occurring skin moisture meaning that the applicator device does not dry out. In-vitro testing proved the device could continually express glue in intervals for up to 90 minutes after device activation.¹

Chris Meredith, Chief Executive Officer of AMS, commented: “LiquiBand Exceed™ has been an excellent addition to our LiquiBand^® topical skin adhesive portfolio demonstrating encouraging initial uptake since its launch this year. These extended US product claims will help us to continue to provide a superior product for clinicians and a versatile solution for healthcare providers in this key market, in which we are focused on growing our market share.“

References:

1. Data on file at Advanced Medical Solutions (Plymouth) Ltd.

2. www.ethicon.com/healthcare-professionals/products/wound-closure/skin-adhesives/dermabond-advanced-topical-skin-adhesive#!description-and-specs

– Ends –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director

Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal^®, LiquiBand^® and RESORBA^® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.

About LiquiBand^® Exceed™

The LiquiBand^® portfolio of topical skin adhesives have been developed to provide the global medical market with innovative wound closure products. The LiquiBand^® devices have been uniquely designed to meet the needs of clinicians and patients for safe, secure and effective topical wound closure.

LiquiBand^® Exceed™ is the newest and most innovative topical skin adhesive to join the LiquiBand^® family of products. LIQUIBAND Exceed™ is a 2-octyl cyanoacrylate adhesive that has a unique felt applicator tip to facilitate even, consistent application. The pure octyl formulation maximizes durability and flexibility while providing high viscosity. LiquiBand^® Exceed™ provides an effective microbial barrier to gram positive, gram negative and fungal microbes. The porous felt applicator tip creates even, consistent application while also preventing squirting and dripping of adhesive. The tip has an elliptical shape to allow for versatility in application technique and can provide wide or narrow application strips.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALFFELLSLFIIE

The post Extended Product Claims for LiquiBand Exceed appeared first on Advanced Medical Solutions.

CE Approval to market new product

AdMedSol — Wed, 02 Sep 2015 07:00:38 +0000

RNS Number : 7735X

Advanced Medical Solutions Grp PLC

02 September 2015

Advanced Medical Solutions Group PLC

(“AMS” or the “Group”)

CE Approval received for antimicrobial foam dressing

Winsford, UK, 01 September 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that it has received CE approval to market its Polyhexamethylene Biguanide (PHMB) non adhesive antimicrobial foam dressing in Europe.

PHMB has been shown to be effective against several bacteria including, amongst others, Staphylococcus Aureus including the methicillin resistant type, (MRSA) and Escherichia Coli (E-Coli). This antimicrobial foam wound dressing may be used throughout the healing process on moderate to heavily exuding chronic and acute wounds that are infected or are at risk of infection and may be used on pressure ulcers, leg and foot ulcers, diabetic ulcers and surgical wounds.

AMS expects to launch this product through its OEM partners in 2015, as well as including it in its ActivHeal^® range of woundcare dressings for the NHS.

Chris Meredith, Chief Executive Officer of AMS, commented: “We are pleased to receive CE approval for this AMS product which strengthens our position in the antimicrobial foam market and look forward to launching it in EU markets and into the NHS later this year.“

– Ends –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director

Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys
Investec Bank plc (NOMAD) & Broker	Tel: +44 (0) 20 7597 5970
Gary Clarence / Daniel Adams / Patrick Robb

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal^®, LiquiBand^® and RESORBA^® as well as supplying under white label.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSUFWFFISESU

The post CE Approval to market new product appeared first on Advanced Medical Solutions.

Non Regulatory Announcement

AdMedSol — Thu, 20 Oct 2011 07:00:25 +0000

RNS Number : 5038Q

Advanced Medical Solutions Grp PLC

20 October 2011

For immediate release: 20 October 2011

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Results of US pilot study on LiquiBand®

effectiveness in closing scalp lacerations

Winsford, UK: Researchers from the University of Florida-Jacksonville, College of Medicine presented the results of a pilot study utilising LiquiBand^® topical skin adhesive at the American College of Emergency Physicians (ACEP) Scientific Assembly in San Francisco, October 15-18, 2011. The study demonstrated the effectiveness of LiquiBand^® in the closure of scalp lacerations.

Dermal adhesives are commonly used for facial wound repairs but are rarely used in the US for scalp wounds. LiquiBand^® is a fast polymerizing, medical grade adhesive (cyanoacrylate) that has been successfully used in Europe for topical skin closure, including closing scalp wounds, for more than ten years. This is, however, the first study in the US that specifically addresses the use of dermal adhesives on scalp wounds. Emergency physicians measured ease-of-use, closure time, wound appearance and complications, while patients assessed wound appearance post-closure and pain levels during application.

The physicians involved in the study found that LiquiBand^® treated scalp wounds very effectively, giving an average score of 4.67 out of 5. Patients reported very low pain scores during the procedures, and all parties indicated that they would use LiquiBand^® again rather than traditiional staples or sutures.

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS commented: “This small pilot study clearly supports what we already knew, namely that LiquiBand^® can be used safely for rapid closure of simple scalp lacerations with minimal pain and excellent cosmetic outcomes. However, the key aspect of this study is that it is the first of its kind in the US. The results pave the way for a larger prospective study to be undertaken, but we believe that the high levels of reported physician and patient satisfaction should give direct support to the already encouraging marketing initiatives of our partners in that key market.”

–ends –

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Paul Hodge, Global Marketing Manager	Tel: +1 404 695 9099

Tavistock Communications	Tel: +44 (0) 20 7920 3150
John West / Chris Munden / Andrew Dunn

Notes to Editors:

About Advanced Medical Solutions Group plc – see www.admedsol.com

Advanced Medical Solutions Group is a global business providing innovative products and brands in the areas of accelerating healing and managing wounds, minimising adverse surgical outcomes and sealing and closing tissue. These products are sold in countries across the globe either directly or through a number of strategic partners and distributors.

AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

For further information on LiquiBand, see www.liquiband.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAMMMMGVLFGMZM

The post Non Regulatory Announcement appeared first on Advanced Medical Solutions.

Further Clinical Evidence

AdMedSol — Mon, 11 Jul 2011 07:00:11 +0000

RNS Number : 0969K

Advanced Medical Solutions Grp PLC

11 July 2011

For Release: 11 July 2011

Advanced Medical Solutions Group plc

(“AMS”)

Further Evidence in Support of AMS Antimicrobial Products

Advanced woundcare dressing effective against 160 different types of

Chronic and Burn Wound Microorganisms, including 29 strains of MRSA

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that, as part of the continued support to its global business partners, two further clinical studies have recently been published, targeted to help drive continued growth in AMS’s key silver alginate woundcare business.

The studies, which were published in both The International Wound Journal and the Journal of Woundcare, demonstrate the antimicrobial efficacy of one of AMS’s commercialised silver alginate dressings in killing 160 chronic and burn wound microorganisms, including 29 strains of the superbug Methicillin-resistant Staphylococcus Aureus (MRSA).

Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS stated:

“We are very pleased with the efficacy results for our silver alginate woundcare products, which continue to prove effective against MRSA, one of the most problematic infections to treat. Our quality silver alginate products, coupled with supporting clinical evidence such as these latest studies, have helped our partners successfully capture 20% of the US$230 million global antimicrobial fibre market in the last five years. We look forward to continued success in this area.”

– ends –

For further enquiries:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director

+44 (0) 1606 545508

Tavistock Communications

John West / Chris Munden / Andrew Dunn

+44 (0) 20 7920 3150

Notes to Editors:

AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAQVLFBFDFLBBL

The post Further Clinical Evidence appeared first on Advanced Medical Solutions.

Official Opening of Winsford Facility

AdMedSol — Thu, 27 Jan 2011 07:00:20 +0000

RNS Number : 1569A

Advanced Medical Solutions Grp PLC

27 January 2011

For Release: 27 January 2011

Advanced Medical Solutions Group plc

(“AMS” or the “Company”)

Official opening of Winsford facility

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces the official opening of its new world-class facility in Winsford, Cheshire. This marks a significant milestone in the development of the business and also celebrates 20 years from the founding of the Company.

The 138,500 sq ft facility incorporates offices, laboratories and warehouse space, as well as new state of the art manufacturing lines, which represent a major upgrade of the operational capability of AMS’s advanced woundcare business.

Dr. Don Evans, Chairman of AMS, stated: “We began this major project in 2008 and I am delighted to confirm that the new facility has been completed on time and on budget. Together with our wound closure operation in Plymouth and our foam facility in the Netherlands, AMS is now well positioned to support substantial growth and we look forward to the next stage of AMS’s development with confidence.”

– ends –

For further enquiries:

Advanced Medical Solutions Group plc +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director

Tavistock Communications +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn / Lydia Eades

Investec Bank plc +44 (0) 20 7597 5970

Gary Clarence / Patrick Robb / Daniel Adams

Notes to Editors:

AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAMMGZMLVZGMZM

The post Official Opening of Winsford Facility appeared first on Advanced Medical Solutions.

AMS Strengthens Senior Management Team

AdMedSol — Tue, 03 Aug 2010 07:00:00 +0000

RNS Number : 4002Q

Advanced Medical Solutions Grp PLC

03 August 2010

3 August 2010

Advanced Medical Solutions Group plc

(“AMS” or “the Company”)

AMS Strengthens Senior Management Team

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that it has strengthened its senior management team with key appointments.

Clare Holden has been appointed Vice President of Research and Development. Clare has over 20 years of process and new product development experience with global organisations such as Smith & Nephew where her last position was as Vice President of New Product Development for their Hull based Wound Management Division. Most recently, Clare was Head of Project Transformations at Siemens’ Automation & Drives Division in Manchester.

In addition, Steve Platt joins as General Manager of AMS’s new world class Winsford facility. Steve brings 16 years of experience in industrial manufacturing and production with multinational organisations including Toyota Manufacturing (UK), JCB Transmissions, RWD Technologies and, most recently, Nilfisk Advance. He has a proven track record formaximising business performance through the implementation of lean project management techniques, including green field site responsibilities.

Chris Meredith, COO of Advanced Medical Solutions commented:

“We are delighted to announce these latest additions to our senior management team, strengthening our research and development and general operational functions. The appointments follow on from the appointments earlier in the year of Brian Dowd, who joined us from Covidien to head up our US Commercial team, and Dr. Andrew Garland, who joined us from 3M to head our European Commercial Team.

“The additions add experience and enthusiasm to our existing team, as we develop our infrastructure to take the Company through the next exciting period of growth and realise the opportunities open for our innovative product portfolio.“

–ends –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer Tel: +44 (0) 1606 545508

Chris Meredith, Chief Operating Officer

Mary Tavener, Finance Director

Tavistock Communications

John West / Andrew Dunn / Chris Munden Tel: +44 (0) 20 7920 3150

Notes to Editors:

AMS advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foam. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. The inclusion of silver adds a proven effectiveness against antibiotic resistant bacteria.

AMS wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). In 2009, AMS delivered a 19% increase in revenues and a 51% increase in operating profit before exceptionals. The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUGWRUPUGMP

The post AMS Strengthens Senior Management Team appeared first on Advanced Medical Solutions.

ActivHealÂ® Cuts Costs

AdMedSol — Wed, 09 Dec 2009 07:00:00 +0000

RNS Number : 8082D

Advanced Medical Solutions Grp PLC

09 December 2009

For immediate release

9 December 2009

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Major London Teaching Hospital endorses financial savings offered by ActivHeal^® range

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that its ActivHeal^® value range of advanced woundcare dressings has delivered annualised cost savings of 54% to University College London Hospitals‘ NHS Foundation Trust (UCLH) whilst maintaining a high standard of clinical care.

These findings were reported in an article entitled “Using ActivHeal^® dressings in a London teaching hospital: a cost analysis” published in a recent edition of the British Journal of Nursing 2009 (Tissue Viability Supplement) Vol 18 No 20, by Sarah Lewis, Tissue Viability Nurse UCLH.

ActivHeal^® is a value range of products provided directly to the NHS by AMS as a first line therapy for routine wounds. These complement the use of AMS’s new technologies, such as silver alginate, which are sold through strategic partners for treating more difficult wounds.

The ActivHeal^® range offers equivalent technical and clinical performance to similar branded products but at a substantially reduced cost thereby delivering real and immediate savings to the NHS. This potential saving is estimated to be of the order of £25 million per year in the UK which helps to balance budgets and afford new technologies for problematic cases. ActivHeal^® products are currently used in around half of the NHS Foundation and Acute Hospital Trusts in the UK. Hospital usage represents around 25% of the current £100 million NHS spend on advanced woundcare dressings with the majority being in the community.

In the study reported in the British Journal of Nursing, the ActivHeal® range of dressings consisting of foams, films, alginates, gels and hydrocolloids were substituted for “branded” dressings over a three-month period in 2007 during which time dressing cost and clinical effectiveness were assessed. The result was an equivalent yearly cost saving of £55,221 (54%) with retention of performance standards across the dressing range.

The study adds: “Two years after the trial, wards in University College London Hospitals NHS Foundation Trust continue to benefit from significant annual cost savings on dressings by using the ActivHeal^® range of products, while maintaining a high standard of clinical care.“

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

“This study, which fully endorsed the ActivHeal^® value offering, is of particular relevance because pressure on healthcare budgets is putting increasing importance on the achievement of cost savings without compromising patient care.

“This “in-use” study at a major London teaching hospital rated the dressings as “equivalent to” or “better than” the original dressings in almost all cases and allowed a significant cost saving to be made by switching to ActivHeal®.”

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: +44 (0) 1606 545508

Buchanan Communications
Mark Court / Stasa Filiplic	Tel: +44 (0) 20 7466 5000

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

The advanced woundcare products are based on the moist wound healing principle. AMS uses its in–house technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection.

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUWAWRKRRURAA

The post ActivHealÂ® Cuts Costs appeared first on Advanced Medical Solutions.

Initial LiquiBandT product introduced to US market

AdMedSol — Fri, 16 Oct 2009 16:03:00 +0000

RNS Number : 9428A

Advanced Medical Solutions Grp PLC

16 October 2009

For immediate release

16 October 2009

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Initial LiquiBand™ product introduced to US market

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that LiquiBand™ topical skin adhesive, the initial product for which the Group received regulatory clearance in February, has been introduced to the US market by MedLogic, its wound closure and sealants division. Further LiquiBand^® products are under review by the FDA.

LiquiBand™, the leading topical skin adhesive in the UK accident and emergency market received 510(k) clearance from the US Food & Drug Administration (FDA) earlier this year, and is indicated for use on trauma induced lacerations, minor wounds and laparoscopic skin incisions.

The product line consisting of LiquiBand and LiquiBand™ Flow Control was unveiled at the American College of Emergency Physicians in Boston, 5-8 October and is being displayed at the American Academy of Pediatrics National Conference and Exposition in Washington DC, 17-20 October .

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

“We are thrilled to bring this exciting technology to clinicians and patients in the United States. LiquiBand™ has been sold successfully for many years in Europe and has enabled MedLogic to establish a leadership position in the use of tissue adhesives for wound closure.

“The products shown at the Emergency Physicians meeting and at the Pediatrics Conference will be commercially available in November via multiple distribution partners and further products will follow to provide a comprehensive suite of products to allow us to compete strongly in the US topical tissue adhesives market currently estimated at around $200m.“

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: +44 (0) 1606 545508

Buchanan Communications
Mark Court / Stasa Filiplic	Tel: +44 (0) 20 7466 5000

Investec Bank plc	Tel: +44 (0) 20 7597 5970
Tim Pratelli / Daniel Adams

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAMFBATMMMBBTL

The post Initial LiquiBandT product introduced to US market appeared first on Advanced Medical Solutions.

Growth Company Investor Show

AdMedSol — Fri, 05 Jun 2009 07:00:00 +0000

RNS Number : 4188T

Advanced Medical Solutions Grp PLC

05 June 2009

For Immediate Release

5 June 2009

RNS REACH

Advanced Medical Solutions Group plc

(“AMS” or “the Company”)

To exhibit at Growth Company Investor Show on 10 June 2009

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that it will be exhibiting at the forthcoming Growth Company Investor Show to be held at the Barbican Exhibition Halls, London, on Wednesday 10 June 2009.

AMS will be represented by Don Evans, Chief Executive, and Chris Meredith, Group Commercial Director, on Stand No 68.

The Company will also be making a formal presentation at 12:30 entitled “Healing Growth Pains with Seaweed, Silver and Superglue”.

Attendees at the show will be welcome to visit AMS’s stand and talk to the Company’s senior management about its growth strategy, along with having the opportunity to view some of the Company’s products.

The Growth Company Investor Show brings together leading small and mid-cap quoted companies giving existing and potential new investors the opportunity to meet and network with the companies’ management teams. Further details are available at

www.growthcompanyinvestorshow.co.uk

-ENDS-

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Don Evans, Chief Executive

Mary Tavener, Finance Director

www.admedsol.com

Buchanan Communications	Tel: +44 (0) 20 7466 5000
Mark Court / Stasa Filiplic

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.

The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUUUBGQUPBGMC

The post Growth Company Investor Show appeared first on Advanced Medical Solutions.